Antithrombotic activities of sulforaphane via inhibiting platelet aggregation and FIIa/FXa

Archives of Pharmacal Research

Volumn 37, Issue 11, 2014, Pages 1454-1463

  Ku, Sae Kwang ^a   Bae, Jong Sup ^b  

^a Daegu Haany University   (South Korea)

^b Kyungpook National University   (South Korea)

Author keywords

Coagulation cascade; Endothelium; Fibrinolysis; Sulforaphane

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; FACTOR IIA; FIBRINOLYTIC AGENT; ISOTHIOCYANIC ACID DERIVATIVE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; SULFORAFAN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL SURVIVAL; CHEMICAL STRUCTURE; DRUG EFFECTS; FEMALE; HUMAN; MALE; METABOLISM; MOUSE; THROMBOCYTE AGGREGATION; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR ENDOTHELIUM; YOUNG ADULT;

ADULT; ANIMALS; CELL SURVIVAL; ENDOTHELIUM, VASCULAR; FACTOR XA; FACTOR XA INHIBITORS; FEMALE; FIBRINOLYTIC AGENTS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; ISOTHIOCYANATES; MALE; MICE; MOLECULAR STRUCTURE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET AGGREGATION; PROTHROMBIN; TISSUE PLASMINOGEN ACTIVATOR; YOUNG ADULT;

EID: 84934283824     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-014-0403-8     Document Type: Article

References (41)

1. Bae, J.S. 2011. Antithrombotic and profibrinolytic activities of phloroglucinol. Food and Chemical Toxicology 49: 1572-1577.
2. Bae, J.S., and A.R. Rezaie. 2008. Protease activated receptor 1 (PAR-1) activation by thrombin is protective in human pulmonary artery endothelial cells if endothelial protein C receptor is occupied by its natural ligand. Thrombosis and Haemostasis 100: 101-109.
3. Berk, B.C., J.I. Abe, W. Min, J. Surapisitchat, and C. Yan. 2001. Endothelial atheroprotective and anti-inflammatory mechanisms. Ann N Y Acad Sci 947: 93-109. discussion 109-11 (2001).
4. Dahlback, B. 2000. Blood coagulation. Lancet 355: 1627-1632.
5. Davie, E.W. 1995. Biochemical and molecular aspects of the coagulation cascade. Thrombosis and Haemostasis 74: 1-6.
6. Davie, E.W., K. Fujikawa, and W. Kisiel. 1991. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 30: 10363-10370.
7. Dejana, E., A. Callioni, A. Quintana, and G. De Gaetano. 1979. Bleeding time in laboratory animals. II. A comparison of different assay conditions in rats. Thrombosis Research 15: 191-197.
8. Despotis, G.J., G. Gravlee, K. Filos, and J. Levy. 1999. Anticoagulation monitoring during cardiac surgery: a review of current and emerging techniques. Anesthesiology 91: 1122-1151.
9. Esmon, C.T. 2005. The interactions between inflammation and coagulation. British Journal of Haematology 131: 417-430.
10. Esmon, C.T., K. Fukudome, T. Mather, W. Bode, L.M. Regan, D.J. Stearns-Kurosawa, and S. Kurosawa. 1999. Inflammation, sepsis, and coagulation. Haematologica 84: 254-259.
11. Fahey, J.W., and P. Talalay. 1999. Antioxidant functions of sulforaphane: A potent inducer of Phase II detoxication enzymes. Food and Chemical Toxicology 37: 973-979.
12. Fareed, J., I. Thethi, and D. Hoppensteadt. 2012. Old versus new oral anticoagulants: Focus on pharmacology. Annual Review of Pharmacology and Toxicology 52: 79-99.
13. Fares, A. 2013. Winter cardiovascular diseases phenomenon. North American Journal of Medical Sciences 5: 266-279.
14. Fischer, K.G. 2007. Essentials of anticoagulation in hemodialysis. Hemodialysis International 11: 178-189.
15. Ghosh, S., M. Ezban, E. Persson, U. Pendurthi, U. Hedner, and L.V. Rao. 2007. Activity and regulation of factor VIIa analogs with increased potency at the endothelial cell surface. Journal of Thrombosis and Haemostasis 5: 336-346.
16. Hamaguchi, E., T. Takamura, A. Shimizu, and Y. Nagai. 2003. Tumor necrosis factor-alpha and troglitazone regulate plasminogen activator inhibitor type 1 production through extracellular signal-regulated kinase- and nuclear factor-kappaB-dependent pathways in cultured human umbilical vein endothelial cells. Journal of Pharmacology and Experimental Therapeutics 307: 987-994.
17. Harbrecht, U. 2011. Old and new anticoagulants. Hamostaseologie 31: 21-27.
18. Heiss, E., C. Herhaus, K. Klimo, H. Bartsch, and C. Gerhauser. 2001. Nuclear factor kappa B is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms. Journal of Biological Chemistry 276: 32008-32015.
19. Jauch, E.C., J.L. Saver, H.P. Adams Jr, A. Bruno, J.J. Connors, B.M. Demaerschalk, P. Khatri, P.W. Mcmullan Jr, A.I. Qureshi, K. Rosenfield, P.A. Scott, D.R. Summers, D.Z. Wang, M. Wintermark, and H. Yonas. 2013. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 44: 870-947.
20. Jayakumar, T., W.F. Chen, W.J. Lu, D.S. Chou, G. Hsiao, C.Y. Hsu, J.R. Sheu, and C.Y. Hsieh. 2013. A novel antithrombotic effect of sulforaphane via activation of platelet adenylate cyclase: ex vivo and in vivo studies. Journal of Nutritional Biochemistry 24: 1086-1095.
21. Kaiser, L., and H.V. Sparks Jr. 1987. Endothelial cells. Not just a cellophane wrapper. Archives of Internal Medicine 147: 569-573.
22. Killeen, M.E., J.A. Englert, D.B. Stolz, M. Song, Y. Han, R.L. Delude, J.A. Kellum, and M.P. Fink. 2006. The phase 2 enzyme inducers ethacrynic acid, DL-sulforaphane, and oltipraz inhibit lipopolysaccharide-induced high-mobility group box 1 secretion by RAW 264.7 cells. Journal of Pharmacology and Experimental Therapeutics 316: 1070-1079.
23. Kim, S.Y., S. Kim, J.M. Kim, E.H. Jho, S. Park, D. Oh, and H.S. Yun-Choi. 2011. PKC inhibitors RO 31-8220 and Go 6983 enhance epinephrine-induced platelet aggregation in catecholamine hypo-responsive platelets by enhancing Akt phosphorylation. BMB Report 44: 140-145.
24. Kim, T.H., S.K. Ku, and J.S. Bae. 2012. Antithrombotic and profibrinolytic activities of eckol and dieckol. Journal of Cellular Biochemistry 113: 2877-2883.
25. Lee, K.H. 2000. Research and future trends in the pharmaceutical development of medicinal herbs from Chinese medicine. Public Health Nutrition 3: 515-522.
26. Lin, W., R.T. Wu, T. Wu, T.O. Khor, H. Wang, and A.N. Kong. 2008. Sulforaphane suppressed LPS-induced inflammation in mouse peritoneal macrophages through Nrf2 dependent pathway. Biochemical Pharmacology 76: 967-973.
27. Lopez, S., F. Peiretti, B. Bonardo, I. Juhan-Vague, and G. Nalbone. 2000. Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. Atherosclerosis 152: 359-366.
28. Mann, K.G., K. Brummel, and S. Butenas. 2003. What is all that thrombin for? Journal of Thrombosis and Haemostasis 1: 1504-1514.
29. Monroe, D.M., M. Hoffman, and H.R. Roberts. 2002. Platelets and thrombin generation. Arteriosclerosis, Thrombosis, and Vascular Biology 22: 1381-1389.
30. Nowak, P., H.M. Zbikowska, M. Ponczek, J. Kolodziejczyk, and B. Wachowicz. 2007. Different vulnerability of fibrinogen subunits to oxidative/nitrative modifications induced by peroxynitrite: functional consequences. Thrombosis Research 121: 163-174.
31. Oh, C.H., J.I. Shin, S.J. Mo, S.J. Yun, S.H. Kim, and Y.H. Rhee. 2013. Antiplatelet activity of l-sulforaphane by regulation of platelet activation factors, glycoprotein IIb/IIIa and thromboxane A2. Blood Coagulation & Fibrinolysis 24: 498-504.
32. Philip-Joet, F., M.C. Alessi, C. Philip-Joet, M. Aillaud, J.R. Barriere, A. Arnaud, and I. Juhan-Vague. 1995. Fibrinolytic and inflammatory processes in pleural effusions. European Respiratory Journal 8: 1352-1356.
33. Popa, C., M.G. Netea, P.L. Van Riel, J.W. Van Der Meer, and A.F. Stalenhoef. 2007. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. Journal of Lipid Research 48: 751-762.
34. Quinn, C., J. Hill, and H. Hassouna. 2000. A guide for diagnosis of patients with arterial and venous thrombosis. Clinical Laboratory Science 13: 229-238.
35. Rao, L.V., S.I. Rapaport, and M. Lorenzi. 1988. Enhancement by human umbilical vein endothelial cells of factor Xa-catalyzed activation of factor VII. Blood 71: 791-796.
36. Ross, R. 1999. Atherosclerosis - an inflammatory disease. New England Journal of Medicine 340: 115-126.
37. Schleef, R.R., M.P. Bevilacqua, M. Sawdey, M.A. Gimbrone Jr, and D.J. Loskutoff. 1988. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. Journal of Biological Chemistry 263: 5797-5803.
38. Schouten, M., W.J. Wiersinga, M. Levi, and T. Van Der Poll. 2008. Inflammation, endothelium, and coagulation in sepsis. Journal of Leukocyte Biology 83: 536-545.
39. Sugo, T., C. Nakamikawa, S. Tanabe, and M. Matsuda. 1995. Activation of prothrombin by factor Xa bound to the membrane surface of human umbilical vein endothelial cells: its catalytic efficiency is similar to that of prothrombinase complex on platelets. Journal of Biochemistry 117: 244-250.
40. Van Den Berg, E.A., E.D. Sprengers, M. Jaye, W. Burgess, T. Maciag, and V.W. Van Hinsbergh. 1988. Regulation of plasminogen activator inhibitor-1 mRNA in human endothelial cells. Thrombosis and Haemostasis 60: 63-67.
41. Van Hinsbergh, V.W., T. Kooistra, E.A. Van Den Berg, H.M. Princen, W. Fiers, and J.J. Emeis. 1988. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood 72: 1467-1473.